ESTRO 2025 - Abstract Book

S1715

Clinical - Sarcoma & skin cancer & malignant melanoma

ESTRO 2025

band free from the circumference (first patient PTV had donut shape thus corridor was inside PTV). RECIST was used to assess primary outcomes. Adverse Events assessed using CTCAE V5.0

Results: Patients and responses shown Table 1. Mean follow-up was 35.3 (3,5-79.8) months. Mean CTV/ PTV volume were 788cc (106-3640) and 1307cc (241-5025). PTV mean V30, V28,5 and V27 were 51%, 88.6% and 96,4%. Mean corridor volume was 1741cc (243-5008). Corridors mean dose V20, V15 and V10 were 13.6%, 25.7% and 53%. AEs are shown in Table 2. Of note is acute edema in the first patient and skin toxicity in the patient who received an integrated boost with nivolumab both resolved.

Conclusion: This innovative technique for ITM in the lower limb resulted in lesion-specific ablation of disease and normal tissue sparing, with minimal local or systemic adverse effects.

Keywords: Tomotherapy, in-transit, melanoma